Product Description: Benralizumab (MEDI-563) is an interleukin-5 receptor α (IL-5Rα)-directed cytolytic monoclonal antibody that induces direct, rapid and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. Benralizumab can be used for severe eosinophilic asthma[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Kolbeck R, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010 Jun;125(6):1344-1353.e2./[2]Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019.
CAS Number: 1044511-01-4
Molecular Weight: N/A
Compound Purity: 99.1
Research Area: Inflammation/Immunology; Cancer
Solubility: H2O
Target: Apoptosis;Interleukin Related
English
Deutsch
